An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases
A legfontosabb adatok
- Ki végzi
- Shanghai Cell Therapy Group Co.,Ltd
- Hol
- Shanghai (Kína)A helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Fázis
- Korai 1. fázis
- Résztvevők
- 20 fő, tervezett
- Kezdés
- 2025. szept. 9.
- Várható befejezés
- 2027. dec.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- CD19/CD22/BCMA CAR-T cells(BZE2204)
- A regiszteradat frissítve
- 2026. november 12.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with active autoimmune disease that came back or did not respond to treatment: lupus (SLE), inflammatory muscle disease (IIM) or low platelets from immune attack (ITP). They get BZE2204 CAR-T cells, made from their own immune cells.
- Életkor
- 18 to 70 years
- Nem
- Men and women
- A betegség stádiuma
- Relapsed or refractory active disease. IIM: moderate to severe (MMT ≤ 141 plus 2 activity criteria, or active lung disease on CT). ITP: diagnosed more than 3 months, platelets <50 ×10^9/L on at least 2 tests. SLE: diagnosed at least 6 months, SLEDAI-2K ≥8, lupus kidney disease class III or IV (or III+V, IV+V) by biopsy within 12 months. Life expectancy > 6 months.
- Korábbi kezelés
- IIM: did not work or not tolerated: corticosteroids and at least 1 immunosuppressant or biologic. ITP: first-line therapy did not work, or no effect or relapse after spleen removal. SLE: did not work or not tolerated: at least one immunosuppressant and/or one biologic; or relapse during maintenance after induction for lupus kidney disease.
- Biomarker vagy leletérték
- IIM: at least one myositis antibody (MSA or MAA) positive. ITP: at least one platelet glycoprotein autoantibody positive. SLE: ANA and/or anti-dsDNA and/or anti-Sm antibody positive. Adequate blood, liver, kidney, clotting and lung tests.
A részvétel fő kizáró okai
- Serious heart disease, or severe nervous system disease within 6 months
- Current cancer or past cancer, with protocol exceptions
- HIV, hepatitis B or C, syphilis, active or untreated tuberculosis, or uncontrolled infection
- Serious bleeding or blood clots within 6 months
- Severe forms of each disease, such as lupus crisis within 3 month, active brain lupus, or ITP with platelets < 10x10^9/L and active bleeding
A regiszter feltételei, szó szerint
Mind a 20 feltétel megnézéseKevesebb
Egyéb feltételek
- Major Inclusion Criteria:
- Males or females, aged 18-70 years old
- Adequate bone marrow, hepatic, renal, coagulation and pulmonary function defined as:; Bone marrow reservation: absolute neutrophil count (ANC) ≥1 ×10\^9/L; absolute lymphocyte count (ALC)≥ 0.5 ×10\^9/L; hemoglobulin ≥80 g/L; platelets ≥50 ×10\^9/L(except for ITP); Hepatic function: i: Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≤ 5 upper limit of normal(ULN) (except for elevations are evaluated to be related to autoimmune disease by investigators)and ii: total bilirubin ≤ 2 ULN, (except for Gilbert's syndrome patients, those with total bilirubin ≤ 3 ULN and direct bilirubin ≤ 1.5 ULN can be enrolled); Renal function: serum creatinine ≤ 1.5 ULN , or estimated glomerular filtration rate(eGFR) ≥ 60 mL/min/1.73m2 [eGFR=186×age\^-0.203×SCr\^-1.154(mg/dl),female×0.742]; Coagulation function: International normalized ratio (INR) or prothrombin time (PT) ≤1.5 ULN; Pulmonary function: Have the minimum level of pulmonary reserve, defined as ≤ CTCAE (Common Terminology Criteria for Adverse Events) grade 1 dyspnea and the SaO2(oxygen saturation)≥ 91% on room air
- Life expectancy > 6 months
- Subjects with relapsed or refractory active IIM also need meet following criteria:; Subjects with suspected or confirmed dermatomyositis(DM), polymyositis(PM), anti-synthetase syndrome(ASS) and immune-mediated necrotizing myopathy(IMNM, need to be assessed by the investigator that the patient has no safety instability) based on the 2017 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria; Positive (+ or above) for at least one myositis-specific antibody (MSA) or myositis-associated antibody (MAA), including anti-TIF-1γ, NXP-2, Mi-2α, Mi-2β, MDA-5, SAE-1/2, SRP, HMGCR, Jo-1, PL-7, PL-12, HA, EJ, OJ, KS, Zo, Tyr, PM-Scl100, PM-Scl75, SSA/Ro-52, SSB/LA, Ku, RNA-PIII, cN1A, etc; At screening, the subject must have moderate to severe IIM, defined as manual muscle testing (MMT) ≤ 141 and 2 of the following criteria are met; or CT suggests active interstitial lung disease(ILD); Physician global activity assessment (PGA) ≥ 2 cm (Visual analogue scale VAS 10 cm); Patient global activity assessment (PtGA) ≥ 2 cm ( VAS 10 cm scale); Extramuscular global assessment (Myositis Disease Activity Assessment Tool [MDAAT]) ≥ 2.0 cm (VAS 10 cm scale); Health assessment questionnaire (HAQ) > 0.25; Elevation in one or more muscle enzymes (CK, LDH, AST, ALT) is ≥ 1.5 ULN; Lack of efficacy or intolerance to corticosteroids and at least 1 immunosuppressant or biologic agents
- Subjects with relapsed or refractory active ITP also need meet following criteria; Diagnosed with ITP for more than 3 months, including primary ITP and ITP secondary to autoimmune diseases; Platelets <50 ×10\^9/L with at least twice tests(≥24h interval); At least one platelet glycoprotein specific autoantibody positive; Lack of efficacy for first line of therapy, or lack of efficacy/relapse post splenectomy
- Subjects with relapsed or refractory active SLE also need meet following criteria; Diagnosed with SLE according to the 2019 EULAR/ACR classification criteria for at least 6 months; Positive autoantibodies: antinuclear antibody (ANA) and/or anti-double strand-DNA(dsDNA) antibody and/or anti-Smith(Sm) antibody; SLEDAI-2K scores ≥8 at screening. If the scores for low complement and/or anti-ds-DNA antibody are available, the SLEDAI-2K scores for clinical symptoms (except low complement and/or anti-ds-DNA antibody) should be ≥6; Proliferative class III or IV , or class III+V or IV+V lupus nephritis(LN) confirmed by biopsies within 12 months; urine protein > 1.0g/24h or urine protein creatinine ratio (UPCR) >1000mg/g and PGA>1; Lack of efficacy or intolerance to at least one immunosuppressant and/or one biologic in medical history; for LN patients, relapse during maintenance post induction therapy is also eligible; Major Exclusion Criteria:
- A history of severe hypersensitivity or allergic reactions, or contraindications or hypersensitivity to any component of the investigational drug
- Presence of any serious heart diseases defined in the protocol
- A medical history of severe central nervous system or symptoms within 6 months
- Any concurrent malignancy or a history of malignancy with exceptions indicated in the protocol
- Clinically significant hemorrhage symptoms or definite bleeding tendencies (except for events caused by ITP) within 6 months prior to screening; arteriovenous thrombosis events within 6 months prior to screening
- Any positive results of contagious diseases as following:; Human immunodeficiency virus (HIV) antibody positive; HBsAg positive; or HBcAb/HBeAb positive (subjects with HBV DNA copy numbers below the lower limit of detection can be enrolled); hepatitis C antibody (HCV-Ab) positive (the subjects with HCV RNA below the lower limit of detection can be enrolled) or a known medical history of hepatitis C; Treponema pallidum antibody (TP-Ab) positive; Epstein-Barr virus(EBV), cytomegalovirus(CMV) antibody positive and copy number is above the limit
- Active tuberculosis or latent tuberculosis that has not been adequately treated
- Evidenced viral, bacterial or fungal infection that is uncontrolled or requires systemic antimicrobial therapy
- Requirements of wash-out period for specific treatment are not met(detailed in protocol)
- Subjects with relapsed or refractory active IIM will be excluded in the following situations:; Inclusion body myositis, amyopathic dermatomyositis or secondary myositis with documented medical history; Severe muscle damage; Uncontrolled extra muscle damage relating to PM or DM
- Subjects with relapsed or refractory active ITP will be excluded if platelet < 10x10\^9/L with active bleeding or bleeding score ≥5
- Subjects with relapsed or refractory active SLE will be excluded if the subject has lupus crisis within 3 month, active CNS lupus, severe hemolytic anemia, severe thrombocytopenic purpura etc
- Any situations evaluated by investigators that may prevent the subjects from participating in the study, or may confound the study results, or participation in this study is not in the best interests of the subjects
Nézd meg, megfelelhetsz-e
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 70 év között vagy?
Helyszínek itt: Kína
- Shanghai Mengchao Cancer HospitalShanghai, KínaContact: Jinxing LouRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
This is a single-arm, open-label, early-phase dose-escalation and expansion study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of autologous CD19/CD22/BCMA trispecific CAR T cells (BZE2204) in patients with relapsed or refractory autoimmune diseases, including systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM) and immune thrombocytopenia (ITP). BZE2204 is manufactured using a rapid, approximately 6-hour process without ex vivo cell expansion and administered without lymphodepleting chemotherapy. The main safety, efficacy and exploratory assessments are conducted through Month 6 after infusion, followed by an extended follow-up phase.
A vizsgálat csoportja
- BZE2204 CAR-T cell therapyA vizsgált kezelés
Kezelés: CD19/CD22/BCMA CAR-T cells(BZE2204)
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- An Exploratory Clinical Study to Evaluate the Safety and Efficacy of BZE2204 CD19/CD22/BCMA CAR-T Cells in Subjects With Relapsed or Refractory Active Autoimmune Diseases
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Illeszkedési kérdések
- Forrás: NCT07174843: ki vehet részt
- A regiszteradat frissítve
- 2026. november 12.